Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Rating Reaffirmed by Needham & Company LLC

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $50.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Yann Mazabraud ,Joseph Shulman ,Analyst Recommendations For Rhythm Pharmaceuticals ,Needham Company ,Wealth Management ,Hennion Walsh Asset Management Inc ,Rhythm Pharmaceuticals Inc ,Virtu Financial ,Goldman Sachs Group ,Institutional Investors Weigh In On Rhythm Pharmaceuticals ,Rhythm Pharmaceuticals Stock Performance ,Vanguard Group Inc ,Wellington Management Group ,Rhythm Pharmaceuticals ,Wells Fargo Company ,News Ratings For Rhythm Pharmaceuticals Daily ,Nasdaq ,Get Free Report ,Walsh Asset Management ,Management Group ,Rhythm Pharmaceuticals Daily ,Nasdaq Rytm ,Rytm ,Medical ,Reiterated Rating ,Needham Company Llc ,